## Edgar Filing: Anzalone Christopher Richard - Form 4

Anzalone Christopher Richard Form 4

January 03, 2	2019											
FORM									OMB AF	PROVAL		
	UNITEL	) STATES			ND EXCI D.C. 2054		GE C	OMMISSION	OMB Number:	3235-0287		
Check th if no long subject to Section 1 Form 4 o Form 5 obligation may cont <i>See</i> Instru 1(b).	6. r Filed pu ns inue.	MENT O ursuant to S 7(a) of the 30(h)	Expires: Estimated a burden hour response									
(Print or Type I	Responses)											
1. Name and Address of Reporting Person <u>*</u> Anzalone Christopher Richard			2. Issuer Name <b>and</b> Ticker or Trading Symbol ARROWHEAD PHARMACEUTICALS, INC.				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) 225 S. LAK 1050	5 S. LAKE AVENUE, SUITE (Month/E) 01/01/2				of Earliest Transaction /Day/Year)				X Director 10% Owner X Officer (give title Other (specify below) Chief Executive Officer			
	(Street) A, CA 91101	endment, Date Original nth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative Se	curiti	es Acqu	uired, Disposed of	, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year	r) Executio any		3. Transactio Code	4. Securitie on(A) or Disp (Instr. 3, 4 a)	s Acqu osed c	uired	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial		
Common Stock	01/01/2019			A	600,000 (1)	A	\$ 0	2,142,455 <u>(2)</u>	D			
Reminder: Ren	ort on a separate li	ne for each cl	ass of secu	rities benef	icially owned	l direc	tly or ii	ndirectly.				

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title o Derivativ Security (Instr. 3)	e Conversion or Exercise	3. Transaction Date (Month/Day/Year)	4. Transac Code (Instr. 8	<ol> <li>5.</li> <li>tionNumber of</li> <li>Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)</li> </ol>	Expiration E (Month/Day re s	6. Date Exercisable and Expiration Date (Month/Day/Year)		ele and unt of rlying rities (1, 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
			Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## Edgar Filing: Anzalone Christopher Richard - Form 4

## **Reporting Owners**

Reporting Owner Name / Address	Relationships							
1 0	Director	10% Owner	Officer	Other				
Anzalone Christopher Richard 225 S. LAKE AVENUE SUITE 1050 PASADENA, CA 91101	X		Chief Executive Officer					
Signatures								
/s/ Chris 0 Anzalone	1/03/2019							

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Represents the maximum number of shares underlying a restricted stock unit that may be earned based on the achievement of three predetermined performance goals related to the advancement of the Company's clinical and preclinical programs and business

- (1) development that must be achieved within two years. If the performance goals are not met within the required time periods, the award will be forfeited in part or in whole.
- Includes a total of 933,333 shares underlying restricted stock units that may be earned based on the achievement of certain performance (2) goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.